Recording of non-musculoskeletal manifestations, comorbidities and safety outcomes in European spondyloarthritis registries: A survey

Zohra F. Ahmadzay, Jette Heberg, Jacob B. Jørgensen, Lykke M. Ørnbjerg, Mikkel Østergaard, Signe Møller-Bisgaard, Brigitte Michelsen, Anne Gitte Loft, Gareth T. Jones, Pasoon Hellamand, Almut Scherer, Michael J. Nissen, Karel Pavelka, Jakub Závada, Karin Laas, Sigrid Vorobjov, Dan Nordström, Tuulikki Sokka-Isler, Anne C. Regierer, Andreas ReichBjorn Gudbjornsson, Katrin Thorarinsdottir, Florenzo Iannone, Ennio Giulio Favalli, Marleen Van De Sande, Sella Aarrestad Provan, Tore K. Kvien, Ana Maria Rodrigues, Cátia F. Gonçalves, Catalin Codreanu, Corina Mogosan, Ziga Rotar, Katja Perdan Prikmajer, Isabel Castrejon, Lucía Otero-Varela, Daniela Di Giuseppe, Johan K. Wallman, Adrian Ciurea, Burkhard Möller, Gökçe Kenar-Artln, Tuba Demirci Ylldlrlm, Gary J. MacFarlane, Ovidiu Rotariu, Bente Glintborg, Merete Lund Hetland

Research output: Contribution to journalArticlepeer-review

4 Downloads (Pure)

Abstract

Objectives: Real-world evidence is needed to inform treatment strategies for patients with PsA and axial SpA (axSpA) who have non-musculoskeletal manifestations (NMMs), various risk factors and comorbidities. International collaboration is required to ensure statistical power and to enhance generalizability. The first step forward is identifying which data are currently being collected. Across 17 registries participating in the European Spondyloarthritis Research Collaboration (EuroSpA), we aimed to map recording practices for NMMs, comorbidities and safety outcomes in patients with PsA and axSpA. Methods: Through a survey with 4,420 questionnaire items, we explored the recording practices of 58 pre-defined conditions (i.e. NMMs, comorbidities and safety outcomes) covering 10 disease areas. In all registries we mapped for each condition whether it was recorded, the recording procedure and the potential to identify it through linkage to other national registries. Results: Conditions were generally recorded at entry into the registry and clinical follow-up visits using a pre-specified list or a coding system. Most registries recorded conditions within the following disease areas: NMMs (number of registries, n = 15-16), cardiovascular diseases (n = 10-14), gastrointestinal diseases (n = 12-13), infections (n = 10-13) and death (n = 14). Nordic countries had the potential for data linkage and generally had limited recording of conditions in their registry, while other countries had comprehensive recording practices. Conclusion: A wide range of conditions were consistently recorded across the registries. The recording practices of many conditions and disease areas were comparable across the registries. Our findings support the potential for future collaborative research.

Original languageEnglish
Article numberrkae135
JournalRheumatology Advances in Practice
Volume8
Issue number4
DOIs
Publication statusPublished - 2024

Keywords

  • biological therapies
  • comorbidity
  • DMARDs
  • JAK inhibitors
  • multimorbidity
  • routinely collected data
  • spondyloarthritis

Cite this